SCHEMBL5034255

SCHEMBL5034255

COCc1cc(OCc2ccccc2)c2nc(C)c(C)n2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 5/20 0.51
ATP4B P51164 5/20 0.51
CYP3A4 P08684 4/20 0.47
CYP2C9 P11712 4/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2D6 P10635 2/20 0.47
MAPK1 P28482 2/20 0.47
MEN1 O00255 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
KMT2A Q03164 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
STAT3 P40763 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP2C19 P33261 1/20 0.43
MCHR1 Q99705 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.40
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216426 0.88 ATP4A (0.58) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL5212872 0.84 ATP4A (0.52) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL4591666 0.81 ATP4A (0.50) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL2193469 0.78 ATP4A (0.76) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL4878917 0.77 CYP3A4 (0.77) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL4591398 0.77 ATP4A (0.47) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL5037317 0.77 BRD4 (0.50) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL5034191 0.74 CYP3A4 (0.33) CYP3A4CYP2C9CYP1A2CYP2D6MEN1
SCHEMBL2191328 0.73 ATP4A (0.69) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL4881836 0.73 CYP3A4 (0.41) ATP4AATP4BCYP3A4CYP2C9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326718-B2 8-Substituted imidazopyridines ALTANA PHARMA AG (DE) 2008-02-05 US disclosed
US-7223771-B2 Tricyclic imidazopyridines ALTANA PHARMA AG (DE) 2007-05-29 US disclosed
US-7223771-B2 Tricyclic imidazopyridines ALTANA PHARMA AG (DE) 2007-05-29 US disclosed
EP-1303519-B1 TRICYCLIC IMIDAZOPYRIDINES ALTANA PHARMA AG (DE) 2007-03-07 EP disclosed
EP-1303519-B1 TRICYCLIC IMIDAZOPYRIDINES ALTANA PHARMA AG (DE) 2007-03-07 EP disclosed
US-7141567-B2 Polysubstituted imidazopyridines as gastric secretion inhibitors ALTANA PHARMA AG (DE) 2006-11-28 US disclosed
EP-1313739-B1 ALKYLATED IMIDAZOPYRIDINE DERIVATIVES ALTANA PHARMA AG (DE) 2006-07-05 EP disclosed
EP-1286993-B1 IMIDAZOPYRIDIN-8-ONES ALTANA PHARMA AG (DE) 2006-06-07 EP disclosed
US-20060100234-A1 8-Substituted imidazopyridines ALTANA PHARMA AG (DE) 2006-05-11 US disclosed
EP-1565465-A1 8-SUBSTITUTED IMIDAZOPYRIDINES ALTANA Pharma AG (DE) 2005-08-24 EP disclosed
EP-1332143-A1 POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS ALTANA Pharma AG (DE) 2003-08-06 EP disclosed
US-20030139412-A1 Tricyclic imidazopyridines ALTANA PHARMA AG (DE) 2003-07-24 US disclosed
EP-1313739-A1 ALKYLATED IMIDAZOPYRIDINE DERIVATIVES ALTANA Pharma AG (DE) 2003-05-28 EP disclosed
EP-1303519-A1 TRICYCLIC IMIDAZOPYRIDINES ALTANA Pharma AG (DE) 2003-04-23 EP disclosed
WO-2001072748-A9 IMIDAZOPYRIDIN-8-ONES ALTANA PHARMA AG (DE) 2003-04-10 WO disclosed
EP-1286993-A1 IMIDAZOPYRIDIN-8-ONES ALTANA Pharma AG (DE) 2003-03-05 EP disclosed
WO-2002034749-A1 POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2002-05-02 WO disclosed
WO-2001072757-A1 TRICYCLIC IMIDAZOPYRIDINES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed
WO-2001072748-A1 IMIDAZOPYRIDIN-8-ONES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed
WO-2001072754-A1 ALKYLATED IMIDAZOPYRIDINE DERIVATIVES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100234-A1 8-Substituted imidazopyridines VIP, GIPR, SI ATP4A 129/4885ATP4B 173/4885CYP3A4 36/4885
US-20030139412-A1 Tricyclic imidazopyridines ALPI, SLC10A2, FABP2 ATP4A 345/4885ATP4B 1692/4885CYP3A4 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.